Imatinib (STI571) IC50 for Cell-based and Cell-free Assays

Imatinib (STI571) is a potent, selective, ATP-competitive BCR-ABL, PDGFR, and c-KIT inhibitor. It affects PI3K/AKT/mTOR, MAPK/ERK, and STAT signaling by binding to the kinase ATP-binding site in its inactive conformation, effectively inhibiting cell proliferation and inducing apoptosis.

🎯 check Imatinib (STI571) product page